A novel Gorilla-derived oncolytic Adenovirus with natural selective replication in cancer cells

This study demonstrates that a novel gorilla-derived oncolytic adenovirus (GRAd32), engineered with a chimeric fiber knob to enhance tumor tropism and armed with an anti-HER3 antibody (EV20), effectively achieves selective replication in cancer cells while inhibiting oncogenic signaling, offering a promising alternative to traditional human adenovirus vectors.

The Gist

Imagine your body is a bustling city, and cancer is a gang of criminals taking over specific neighborhoods (tumors). For years, doctors have tried to send in a "police force" made of viruses to hunt down these criminals. The most common police force used so far is based on a human virus called Adenovirus Type 5 (HAd5).

But there are two big problems with this old police force:

1. Everyone knows them: Most people have already fought this virus before, so their immune systems recognize and block it immediately. It's like the criminals have a "Wanted" poster of the police officer on every wall.
2. They aren't picky enough: Sometimes, the virus gets confused and attacks healthy citizens (normal cells) along with the criminals.

The New Solution: A Gorilla Cop

In this study, scientists from ReiThera and the University of Chieti-Pescara decided to try a different kind of police officer: a Gorilla-derived virus (GRAd).

Think of this new virus as a "special forces" unit from a different country (Gorilla land). Because humans haven't met these gorilla viruses before, our immune systems don't recognize them. They can slip past the guards (pre-existing immunity) and get right into the city.

The Two Types of Gorilla Cops

The researchers found two main types of these gorilla viruses:

• The "Wild Card" (GRAdB): This one is very aggressive. It attacks almost everything it touches, both criminals and innocent bystanders. It's too dangerous to use on its own.
• The "Sniper" (GRAdC): This one is special. It has a natural ability to only attack the criminals (cancer cells) and completely ignore the innocent bystanders (normal cells). It's like a sniper who only shoots the bad guys and never misses.

However, the "Sniper" had a flaw: it was a bit slow to find the criminals. It could only enter certain types of cancer cells, missing others.

The Masterpiece: The Chimera (The Hybrid Cop)

To fix this, the scientists performed a clever piece of genetic "surgery." They took the body of the Sniper (GRAdC)—which knows how to be selective and safe—and swapped its "helmet" (the fiber knob) with the helmet of the Wild Card (GRAdB).

• The Result: A new hybrid virus called GRAd32Fk25.
• How it works: The new helmet allows the virus to recognize and enter a much wider variety of cancer cells (like a universal key). But because the body is still the "Sniper," once it's inside, it still refuses to hurt normal cells. It's like giving a precise sniper a better pair of binoculars so they can spot more enemies, but they still only shoot the bad guys.

The "Trojan Horse" Strategy

The scientists didn't stop there. They wanted this virus to do even more than just kill cancer cells directly. They turned the virus into a mobile factory.

They programmed the virus to carry a secret weapon: a tiny piece of a powerful drug called EV20 (an antibody that blocks a specific signal cancer cells use to grow).

• The Plan: The virus enters the cancer cell, starts replicating, and acts as a factory, churning out this drug inside the tumor.
• The Benefit: The drug is only made where the virus is active (inside the tumor). It doesn't flood the whole body, which reduces side effects. It's like sending a delivery truck that only drops off medicine at the specific house where the criminals are hiding, rather than mailing it to every house in the city.

The Results

When they tested this new "Gorilla Hybrid" in the lab:

1. It found more targets: It successfully entered and killed a wider range of cancer cells (lung, breast, ovarian) than the original Sniper.
2. It stayed safe: It still ignored normal, healthy cells.
3. It worked as a factory: The cancer cells infected by the virus started producing the EV20 drug, which successfully blocked the cancer's growth signals.

The Bottom Line

This paper introduces a promising new tool for cancer treatment. By using a rare gorilla virus, the scientists created a "smart bomb" that:

• Hides from the immune system (because it's from a gorilla).
• Only explodes inside cancer cells (natural selectivity).
• Can be upgraded to enter more types of cancer (fiber swapping).
• Turns the cancer cell itself into a factory to produce more medicine (in-situ antibody production).

It's a step toward a future where we can treat cancer with a virus that is smart enough to know the difference between a friend and a foe, and strong enough to fight back without hurting the patient.

Technical Summary

1. Problem Statement

Oncolytic virotherapy (OV) is a promising cancer treatment strategy, but its clinical success has been limited by the dominance of Human Adenovirus type 5 (HAd5) as the primary vector. HAd5-based vectors face two major hurdles:

1. Preexisting Immunity: High seroprevalence of neutralizing antibodies against HAd5 in the human population reduces therapeutic efficacy.
2. Suboptimal Selectivity: Achieving tumor-specific replication in HAd5 requires extensive genetic modifications (e.g., E1 deletions or fiber engineering), which can compromise viral fitness or manufacturability.
3. Biodistribution: HAd5 is prone to sequestration in the liver and spleen upon systemic administration, limiting tumor delivery.

The authors sought to identify an alternative adenoviral platform that naturally possesses tumor selectivity, low seroprevalence, and distinct biodistribution properties without requiring complex genetic attenuation.

2. Methodology

The study employed a multi-step approach involving phylogenetic analysis, viral engineering, and extensive in vitro characterization:

• Phylogenetic Classification: The researchers analyzed gorilla-derived adenoviruses (GRAd) from their collection, classifying them into Group B (GRAdBs: GRAd13, 18, 25, 54) and Group C (GRAdCs: GRAd23, 32) based on hexon, fiber, and polymerase gene sequences.
• Replication and Cytotoxicity Screening: They compared the replication profiles and metabolic impact of GRAdBs, GRAdCs, and HAd5 across a panel of cancer cell lines (lung, breast, ovarian, glioblastoma) and normal cell lines (MRC5, HUVEC) using MTS assays, hexon immunostaining, and droplet digital PCR (ddPCR).
• Receptor Analysis: Flow cytometry was used to quantify surface expression of Coxsackievirus and Adenovirus Receptor (CAR) and CD46. The role of CD46 in entry was confirmed using blocking antibodies.
• Viral Engineering (Chimeric Vector): To broaden the tropism of the selective GRAd32 (Group C), the authors replaced its native fiber knob domain with that of the Group B GRAd25. This created a chimeric vector, GRAd32Fk25, designed to utilize CD46 for entry while retaining the Group C replication machinery.
• Arming with Therapeutic Payload: The chimeric GRAd32Fk25 was further engineered to express a single-chain Fc (scFv-Fc) derivative of the anti-HER3 antibody EV20 within the E3 region. This was done to create a "biofactory" that produces the therapeutic antibody specifically within replicating tumor cells.
• Functional Assays:
  • Expression: Western blotting and ELISA confirmed the production and binding affinity of the GRAd-produced EV20.
  • Signaling Inhibition: Western blotting assessed the inhibition of the HER3/PI3K/Akt pathway in tumor cells treated with virus-derived supernatants.
  • Selectivity: Comparisons were made between the chimeric virus and parental strains in normal vs. tumor cells to ensure selectivity was preserved.

3. Key Contributions

• Discovery of Natural Selectivity: Identification of GRAd32 (Group C) as a novel oncolytic vector that exhibits natural tumor-selective replication, sparing normal cells without the need for E1-based genetic deletions.
• Fiber Retargeting Strategy: Successful generation of GRAd32Fk25, a chimeric vector that combines the CD46-mediated entry of Group B viruses with the selective replication constraints of Group C viruses. This broadens tumor tropism while maintaining a high tumor-to-normal replication ratio.
• In Situ Antibody Production: Demonstration that the chimeric virus can function as a biofactory for the localized production of a functional anti-HER3 antibody (EV20 scFv-Fc), restricting therapeutic activity to the tumor microenvironment.
• Biodistribution Hypothesis: Proposing that GRAd32, sharing homology with GC46 (a gorilla adenovirus with natural lung tropism and low liver sequestration), may be intrinsically suitable for systemic (intravenous) administration, unlike HAd5.

4. Key Results

• Phylogeny: GRAd25 (Group B) and GRAd32 (Group C) were confirmed as distinct from HAd5.
• Replication Profiles:
  • GRAd25 (Group B): Replicated robustly in both tumor and normal cells (low selectivity).
  • GRAd32 (Group C): Replicated efficiently in specific lung cancer lines (A549, NCI-H727) but showed minimal replication in normal cells (MRC5) and other cancer lines.
  • GRAd32Fk25 (Chimera): Showed enhanced entry and replication in tumor cells (comparable to GRAd25) but retained the restricted replication profile in normal cells (similar to GRAd32).
• Tropism Expansion: The chimeric fiber allowed GRAd32 to infect and replicate in breast (MCF-7) and ovarian (SK-OV-3) cancer cells, which the parental GRAd32 could not. However, it did not overcome post-entry blocks in glioblastoma cells.
• Antibody Production:
  • GRAd32Fk25 infected tumor cells produced high levels of functional EV20 scFv-Fc.
  • Normal cells (MRC5) infected with the chimera produced negligible amounts of the antibody, confirming replication-dependent expression.
• Mechanism of Action:
  • The virus-produced EV20 successfully bound to HER3 on tumor cells.
  • Treatment with virus-derived supernatants significantly reduced phosphorylated Akt (p-Akt) levels, confirming the inhibition of the PI3K/Akt oncogenic pathway.
• Selectivity: The chimeric virus maintained a favorable tumor-to-normal replication ratio, outperforming HAd5 in terms of selectivity while offering broader tumor coverage than the parental GRAd32.

5. Significance

This study presents a significant advancement in oncolytic virotherapy by introducing a gorilla-derived platform that overcomes the limitations of current HAd5-based therapies.

• Clinical Potential: The natural selectivity of GRAd32 reduces the need for complex genetic attenuation, potentially improving viral fitness and manufacturing yields.
• Systemic Delivery: The low seroprevalence of GRAd32 and its predicted lack of liver sequestration (based on homology to GC46) suggest it could be administered intravenously, a major hurdle for HAd5.
• Synergistic Therapy: The "armed" vector (GRAd32Fk25-EV20) offers a dual mechanism of action: direct oncolysis and localized, tumor-restricted delivery of a targeted antibody. This approach minimizes systemic toxicity associated with systemic antibody administration while maximizing therapeutic concentration at the tumor site.
• Future Outlook: The platform warrants further investigation in in vivo models to validate biodistribution, safety, and the synergistic efficacy of the oncolytic-antibody combination in immunocompetent settings.